The latest price target for Quest Diagnostics (NYSE:DGX) was reported by Leerink Partners on January 6, 2025. The analyst firm set a price target for $174.00 expecting DGX to rise to within 12 months (a possible 13.99% upside). 28 analyst firms have reported ratings in the last year.

The latest analyst rating for Quest Diagnostics (NYSE:DGX) was provided by Leerink Partners, and Quest Diagnostics upgraded their outperform rating.

The last upgrade for Quest Diagnostics Inc happened on January 6, 2025 when Leerink Partners raised their price target to $174. Leerink Partners previously had a market perform for Quest Diagnostics Inc.

The last downgrade for Quest Diagnostics Inc happened on May 2, 2023 when B of A Securities changed their price target from $166 to $148 for Quest Diagnostics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Quest Diagnostics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Quest Diagnostics was filed on January 6, 2025 so you should expect the next rating to be made available sometime around January 6, 2026.

While ratings are subjective and will change, the latest Quest Diagnostics (DGX) rating was a upgraded with a price target of $169.00 to $174.00. The current price Quest Diagnostics (DGX) is trading at is $152.65, which is out of the analyst’s predicted range.